ELVN Scorecard | ENLIVEN THERAPEUTICS, INC.

ENLIVEN THERAPEUTICS, INC. (ELVN) Scorecard

2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.

40 QUARTERS × 3 ROAST BATTLES

11/120 All 120 Win/Lose results shown below

Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.

Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026

Complete point ledger

Each cell identifies the missing side explicitly.

Quarter	Total return	Revenue growth	EPS growth
2026-Q21/3	WinELVN / S&P 29.46% / 15.20%	LoseELVN / S&P ELVN unavailable / 15.00%	LoseELVN / S&P -16.50% / 50.40%
2026-Q11/3	WinELVN / S&P 154.55% / -4.33%	LoseELVN / S&P ELVN unavailable / 11.30%	LoseELVN / S&P -13.02% / 27.70%
2025-Q40/3	LoseELVN / S&P -24.77% / 2.65%	LoseELVN / S&P ELVN unavailable / 9.00%	LoseELVN / S&P -1.59% / 13.40%
2025-Q30/3	LoseELVN / S&P 2.04% / 8.12%	LoseELVN / S&P ELVN unavailable / 4.61%	LoseELVN / S&P -2.65% / 13.45%
2025-Q20/3	LoseELVN / S&P 1.93% / 10.94%	LoseELVN / S&P ELVN unavailable / 4.83%	LoseELVN / S&P 4.17% / 10.63%
2025-Q10/3	LoseELVN / S&P -12.53% / -4.27%	LoseELVN / S&P ELVN unavailable / 4.98%	LoseELVN / S&P 0.00% / 10.57%
2024-Q40/3	LoseELVN / S&P -11.90% / 2.41%	LoseELVN / S&P ELVN unavailable / 5.25%	LoseELVN / S&P -13.30% / 6.15%
2024-Q31/3	WinELVN / S&P 9.29% / 5.89%	LoseELVN / S&P ELVN unavailable / 5.89%	LoseELVN / S&P -59.09% / 6.11%
2024-Q21/3	WinELVN / S&P 32.86% / 4.28%	LoseELVN / S&P ELVN unavailable / 5.38%	LoseELVN / S&P -73.98% / 5.12%
2024-Q11/3	WinELVN / S&P 27.10% / 10.56%	LoseELVN / S&P ELVN unavailable / 5.71%	LoseELVN / S&P -80.47% / 5.59%
2023-Q40/3	LoseELVN / S&P 1.32% / 11.69%	LoseELVN / S&P ELVN unavailable / 6.81%	LoseELVN / S&P -81.89% / 7.78%
2023-Q30/3	LoseELVN / S&P -33.07% / -3.27%	LoseELVN / S&P ELVN unavailable / 7.52%	LoseELVN / S&P -54.62% / -5.03%
2023-Q21/3	LoseELVN / S&P -6.80% / 8.74%	LoseELVN / S&P ELVN unavailable / 9.50%	WinELVN / S&P -3.53% / -8.57%
2023-Q12/3	WinELVN / S&P 33.86% / 7.50%	LoseELVN / S&P ELVN unavailable / 10.77%	WinELVN / S&P 77.76% / -15.69%
2022-Q41/3	WinELVN / S&P 79.39% / 7.56%	LoseELVN / S&P ELVN unavailable / 11.88%	LoseELVN / S&P ELVN unavailable / -17.99%
2022-Q31/3	WinELVN / S&P 86.89% / -4.88%	LoseELVN / S&P ELVN unavailable / 13.47%	LoseELVN / S&P ELVN unavailable / -1.41%
2022-Q20/3	LoseELVN / S&P -35.11% / -16.10%	LoseELVN / S&P ELVN unavailable / 13.71%	LoseELVN / S&P ELVN unavailable / 11.04%
2022-Q10/3	LoseELVN / S&P -16.44% / -4.60%	LoseELVN / S&P ELVN unavailable / 15.97%	LoseELVN / S&P ELVN unavailable / 42.23%
2021-Q40/3	LoseELVN / S&P -44.85% / 11.03%	LoseELVN / S&P ELVN unavailable / 15.00%	LoseELVN / S&P ELVN unavailable / 96.40%
2021-Q30/3	LoseELVN / S&P -48.35% / 0.58%	LoseELVN / S&P ELVN unavailable / 10.77%	LoseELVN / S&P ELVN unavailable / 69.42%
2021-Q20/3	LoseELVN / S&P -6.40% / 8.55%	LoseELVN / S&P ELVN unavailable / 6.58%	LoseELVN / S&P ELVN unavailable / 51.81%
2021-Q10/3	LoseELVN / S&P -61.72% / 6.17%	LoseELVN / S&P ELVN unavailable / -1.06%	LoseELVN / S&P ELVN unavailable / 7.39%
2020-Q40/3	LoseELVN / S&P 8.41% / 12.15%	LoseELVN / S&P ELVN unavailable / -3.72%	LoseELVN / S&P ELVN unavailable / -33.42%
2020-Q30/3	LoseELVN / S&P -26.38% / 8.93%	LoseELVN / S&P ELVN unavailable / -2.04%	LoseELVN / S&P ELVN unavailable / -27.10%
2020-Q21/3	WinELVN / S&P 72.36% / 20.54%	LoseELVN / S&P ELVN unavailable / -0.46%	LoseELVN / S&P ELVN unavailable / -27.11%
2020-Q10/3	LoseELVN / S&P ELVN unavailable / -19.60%	LoseELVN / S&P ELVN unavailable / 3.47%	LoseELVN / S&P ELVN unavailable / -14.75%
2019-Q40/3	LoseELVN / S&P ELVN unavailable / 9.07%	LoseELVN / S&P ELVN unavailable / 5.36%	LoseELVN / S&P ELVN unavailable / 2.99%
2019-Q30/3	LoseELVN / S&P ELVN unavailable / 1.70%	LoseELVN / S&P ELVN unavailable / 5.02%	LoseELVN / S&P ELVN unavailable / 0.21%
2019-Q20/3	LoseELVN / S&P ELVN unavailable / 4.30%	LoseELVN / S&P ELVN unavailable / 6.64%	LoseELVN / S&P ELVN unavailable / 8.65%
2019-Q10/3	LoseELVN / S&P ELVN unavailable / 13.65%	LoseELVN / S&P ELVN unavailable / 8.12%	LoseELVN / S&P ELVN unavailable / 14.29%
2018-Q40/3	LoseELVN / S&P ELVN unavailable / -13.52%	LoseELVN / S&P ELVN unavailable / 9.05%	LoseELVN / S&P ELVN unavailable / 18.23%
2018-Q30/3	LoseELVN / S&P ELVN unavailable / 7.71%	LoseELVN / S&P ELVN unavailable / 10.21%	LoseELVN / S&P ELVN unavailable / 19.06%
2018-Q20/3	LoseELVN / S&P ELVN unavailable / 3.43%	LoseELVN / S&P ELVN unavailable / 9.03%	LoseELVN / S&P ELVN unavailable / 14.46%
2018-Q10/3	LoseELVN / S&P ELVN unavailable / -0.76%	LoseELVN / S&P ELVN unavailable / 7.68%	LoseELVN / S&P ELVN unavailable / 12.46%
2017-Q40/3	LoseELVN / S&P ELVN unavailable / 6.64%	LoseELVN / S&P ELVN unavailable / 7.03%	LoseELVN / S&P ELVN unavailable / 13.82%
2017-Q30/3	LoseELVN / S&P ELVN unavailable / 4.48%	LoseELVN / S&P ELVN unavailable / 5.68%	LoseELVN / S&P ELVN unavailable / 17.57%
2017-Q20/3	LoseELVN / S&P ELVN unavailable / 3.09%	LoseELVN / S&P ELVN unavailable / 4.83%	LoseELVN / S&P ELVN unavailable / 17.74%
2017-Q10/3	LoseELVN / S&P ELVN unavailable / 6.07%	LoseELVN / S&P ELVN unavailable / 3.67%	LoseELVN / S&P ELVN unavailable / 13.32%
2016-Q40/3	LoseELVN / S&P ELVN unavailable / 3.82%	LoseELVN / S&P ELVN unavailable / 2.09%	LoseELVN / S&P ELVN unavailable / 7.05%
2016-Q30/3	LoseELVN / S&P ELVN unavailable / 3.85%	LoseELVN / S&P ELVN unavailable / 0.20%	LoseELVN / S&P ELVN unavailable / -3.15%

Dividend-reinvested, split-adjusted total return

1Y · 2025-08-29 to 2026-08-27

Metric	ELVN total return	S&P 500 Total Return Index
Total return	198.47%	20.78%
Annualized return	198.47%	20.78%

5Y · 2021-09-01 to 2026-08-27

Metric	ELVN total return	S&P 500 Total Return Index
Total return	217.75%	83.14%
Annualized return	26.01%	12.86%

10Y · 2020-03-12 to 2026-08-27

Metric	ELVN total return	S&P 500 Total Return Index
Total return	0.83%	319.30%
Annualized return	0.08%	15.41%

Calculation rules

window: Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
return Basis: Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
point Rule: Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
frequency: Quarter endpoints only.
fundamentals: Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
non Scoring

Snapshot captured 2026-09-04.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
Arcus Biosciences, Inc. (RCUS)	United States	$3.188B	-8.52
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Organon & Co. (OGN)	United States	$3.603B	17.03
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
PRECIGEN, INC. (PGEN)	United States	$2.757B	-12.94
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59